Pharmacokinetics and ADME optimization in drug discovery

Cancer Drug Design and Discovery

Volumn , Issue , 2008, Pages 131-153

  Stoner, Chad L ^a   Troutman, Matthew D ^a   Laverty, Caroline E ^b  

^a PFIZER INC   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882486368     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369448-5.50009-4     Document Type: Chapter

References (110)

1. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
2. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst. 1991, 8:305-330.
3. Artursson P., Borchardt R.T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 1997, 14:1655-1658.
4. Augustijns P.F., Bradshaw T.P., Gan L.S. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 1993, 197:360-365.
5. Avdeef A. pH-metric solubility 1. Solubility-pH profiles from Bjerrum plots. Pharmacy Pharmacol. Comm. 1998, 4:165-178.
6. Avdeef A., Testa B. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol. Life Sci. 2002, 59:1681-1689.
7. Bates S.E., Robey R., Miyake K. The role of half-transporters in multidrug resistance. J. Bioenerg. Biomembr. 2001, 33:503-511.
8. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 2002, 71:115-123.
9. Benet L.Z., Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol. Pathol. 1995, 23:115-123.
10. Bergstrom C.A., Norinder U., Luthman K., Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm. Res. 2002, 19:182-188.
11. Bevan C.D., Lloyd R.S. A high-throughout screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Analyt. Chem. 2000, 72:1781-1787.
12. Blasko A., Leahy-Dios A., Nelson W.O. Revisiting the solubility concept of pharmaceutical compounds. Monatshefte fur Chemie 2001, 132:789-798.
13. Booth C.L., Pollack G.M., Brouwer K.L. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 1996, 23:771-780.
14. Bu H.Z., Poglod M., Micetich R.G., Khan J.K. High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14:523-528.
15. Cai H., Stoner C., Reddy A. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Intl J. Pharm. 2006, 308:133-139.
16. Camenisch G., Alsenz J., van de Waterbeemd H., Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 1998, 6:317-324.
17. Carlton L.D., Pollack G.M., Brouwer K.L. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin, implications for patients with congestive heart failure receiving epoprostenol. J. Pharm. Sci. 1996, 85:473-477.
18. Chiou W.L., Chung S.M., Wu T.C. Commentary: potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm. Res. 2000, 17:901-903.
19. Cho M.J., Thompson D.P., Cramer C.T. The Madin-Darby canine kidney (MDCK) epithelialcell monolayer as a model cellular transport barrier. Pharm. Res. 1989, 6:71-77.
20. Cho M.J., Adson A., Kezdy F.J. Transepithelial transport of aliphatic carboxylic acids studied in Madin-Darby canine kidney (MDCK) cell monolayers. Pharm. Res. 1990, 7:325-331.
21. Comer J.E., Tam K.Y. Lipophilicity Profiles: Theory and Measurement 2001, Verlag Helvetica Chimica Acta, Zurich.
22. de Lannoy I.A., Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 1992, 189:551-557.
23. Di L., Kerns E.H., Fan K. High-throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38:223-232.
24. Dorr M.B., Pollack G.M. Specific assay for the quantitation of indocyanine green in rat plasma using high-performance liquid chromatography with fluorescence detection. J. Pharm. Sci. 1989, 78:328-333.
25. Doyle L.A., Yang W., Abruzzo L.V. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 1998, 95:15665-15670.
26. Fromm M.F., Busse D., Kroemer H.K., Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996, 24:796-801.
27. Fung E.N., Chen Y.H., Lau Y.Y. Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 795:187-194.
28. Gan L.S., Moseley M.A., Khosla B. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. 1996, 24:344-349.
29. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62:385-427.
30. Gottesman M.M., Hrycyna C.A., Schoenlein P.V. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 1995, 29:607-649.
31. Green C.E., Abraham M.H., Acree W.E. Solvation descriptors for pesticides from the solubility of solids: Diuron as an example. Pest Management Sci. 2000, 56:1043-1053.
32. Green C.E., Saunders K., Gibson D., et al. ALIAS - Automated Laboratory In Vitro Assay System. International Symposium on Laboratory Automation 2003.
33. Greiner B., Eichelbaum M., Fritz P. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104:147-153.
34. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Topics Med. Chem. 2001, 1:385-401.
35. Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96:736-749.
36. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992, 8:67-113.
37. Higgins C.F. P-glycoprotein and cell volumeactivated chloride channels. J. Bioenerg. Biomembr. 1995, 27:63-70.
38. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem. Sci. 1992, 17:18-21.
39. Hilgers A.R., Conradi R.A., Burton P.S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 1990, 7:902-910.
40. Hori R., Okamura N., Aiba T., Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. Exper. Ther. 1993, 266:1620-1625.
41. Hunter J., Hirst B.H., Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 1993, 10:743-749.
42. Ito K., Suzuki H., Horie T., Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 2005, 22:1559-1577.
43. Johnson T.N., Rostami-Hodjegan A., Tucker G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 2006, 45:931-956.
44. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
45. Kangas H., Kotiaho T., Salminen T., Kostiainen R. N-in-one determination of retention factors for drugs by immobilized artificial membrane chromatography coupled to atmospheric pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2001, 15:1501-1505.
46. Kansy M., Senner F., Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 1998, 41:1007-1010.
47. Kim R.B., Fromm M.F., Wandel C. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101:289-294.
48. Knight B., Troutman M., Thakker D.R. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A, a major challenge. Curr. Opin. Pharmacol. 2006, 6:528-532.
49. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab. Dispos. 1998, 26:1202-1212.
50. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
51. Litman T., Zeuthen T., Skovsgaard T., Stein W.D. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1997, 1361:169-176.
52. Litman T., Zeuthen T., Skovsgaard T., Stein W.D. Structure-activity relationships of P-glycoprotein interacting drugs, kinetic characterization of their effects on ATPase activity. Biochim. Biophys. Acta 1997, 1361:159-168.
53. Liu M.J., Scott K.R., Pollack G.M. Pharmacokinetics and pharmacodynamics of valproate analogues in rats I. Spiro{4.6}undecane-2carboxylic acid. Epilepsia 1990, 31:465-473.
54. Lombardo F., Shalaeva M.Y., Tupper K.A. ElogDoct: a tool for lipophilicity determination in drug discovery. J. Med. Chem. 2000, 43:2922-2928.
55. Lombardo F., Shalaeva M.Y., Tupper K.A., Gao F. ElogD(oct): a tool for lipophilicity determination in drug discovery 2. Basic and neutral compounds. J. Med. Chem. 2001, 44:2490-2497.
56. Lombardo F., Obach R.S., Shalaeva M.Y., Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 2002, 45:2867-2876.
57. Lombardo F., Obach R.S., Shalaeva M.Y., Gao F. Prediction of human volume of distribution values for neutral and basic drugs 2. Extended data set and leave-class-out statistics. J. Med. Chem. 2004, 47:1242-1250.
58. Mahmood I., Balian J.D. The pharmacokinetic principles behind scaling from preclinical results to Phase I protocols. Clin. Pharmacokinet. 1999, 36:1-11.
59. Manners C.N., Payling D.W., Smith D.A. Distribution coefficient, a convenient term for the relation of predictable physico-chemical properties to metabolic processes. Xenobiotica 1988, 18:331-350.
60. Masimirembwa C.M., Thompson R., Andersson T.B. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb. Chem. High Throughput Screen 2001, 4:245-263.
61. Maurel P. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Deliv. Rev. 1996, 22:105-132.
62. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27:1350-1359.
63. Paine M.F., Khalighi M., Fisher J.M. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exper. Ther. 1997, 283:1552-1562.
64. Pan L., Ho Q., Tsutsui K., Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. 2001, 90:521-529.
65. Pastan I., Gottesman M.M., Ueda K. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl Acad. Sci. USA 1988, 85:4486-4490.
66. Poole S.K., Durham D., Kibbey C. Rapid method for estimating the octanol-water partition coefficient (log P ow) by microemulsion electrokinetic chromatography. J. Chromatogr. B Biomed. Sci. Appl. 2000, 745:117-126.
67. Ripp S.L., Mills J.B., Fahmi O.A. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab. Dispos. 2006, 34:1742-1748.
68. Rowland M., Tozer T.N. Clinical Pharmacokinetics. Concepts and Applications 1995, Lippincott, Williams & Wilkins, Baltimore.
69. Roymans D., Annaert P., van Houdt J. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. 2005, 33:1004-1016.
70. Saitoh H., Aungst B.J. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 1995, 12:1304-1310.
71. Schinkel A.H. Pharmacological insights from P-glycoprotein knockout mice. Intl J. Clin. Pharmacol. Ther. 1998, 36:9-13.
72. Schinkel A.H., Kemp S., Dolle M. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 1993, 268:7474-7481.
73. Schinkel A.H., Smit J.J., van Tellingen O. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
74. Schinkel A.H., Mol C.A., Wagenaar E. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 1995, 31A:1295-1298.
75. Schinkel A.H., Wagenaar E., van Deemter L. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 1995, 96:1698-1705.
76. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1998, 251:252-261.
77. Sharom F.J. Characterization and functional reconstitution of the multidrug transporter. J. Bioenerg. Biomembr. 1995, 27:15-22.
78. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 1997, 160:161-175.
79. Sharom F.J. The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity. Biochem. Soc. Trans. 1997, 25:1088-1096.
80. Sharom F.J., Yu X., Doige C.A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 1993, 268:24197-24202.
81. Sharom F.J., Yu X., Chu J.W., Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem. J. 1995, 308:381-390.
82. Singh S.S. Preclinical pharmacokinetics: an approach towards safer and effi cacious drugs. Curr. Drug Metab. 2006, 7:165-182.
83. Smit J.J., Schinkel A.H., Oude Elferink R.P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
84. Spahn-Langguth H., Baktir G., Radschuweit A. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Intl J. Clin. Pharmacol. Ther. 1998, 36:16-24.
85. Sparreboom A., van Asperen J., Mayer U. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl Acad. Sci. USA 1997, 94:2031-2035.
86. Stanley L.A., Horsburgh B.C., Ross J. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab. Rev. 2006, 38:515-597.
87. Stein W.D. Kinetics of the P-glycoprotein, the multidrug transporter. Exper. Physiol. 1998, 83:221-232.
88. Stein W.D., Cardarelli C., Pastan I., Gottesman M.M. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol. Pharmacol. 1994, 45:763-772.
89. Stoner C.L., Cleton A., Johnson K. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Intl J. Pharm. 2004, 269:241-249.
90. Stoner C.L., Troutman M., Gao H. Moving in silico screening into practice: a minimalist approach to guide permeability screening. Lett. Drug Design Discov. 2006, 3:575-581.
91. Taylor S., Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J. Pharm. Biomed. Anal. 2006, 41:299-303.
92. Terao T., Hisanaga E., Sai Y. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 1996, 48:1083-1089.
93. Testa B., van de Waterbeemd H., Folkers G., Guy R. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies 2001, Verlag Helvetica Chimica Acta, Zurich.
94. Testa B., Kramer S., Wunderli-Allenspach H., Folkers G. Pharmacokinetic Profiling in Drug Research - Biological, Physicochemical and Computational Strategies 2006, Wiley-VCH, Zurich.
95. Theil F.P., Guentert T.W., Haddad S., Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 2003, 138:29-49.
96. Thiebaut F., Tsuruo T., Hamada H. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 1987, 84:7735-7738.
97. Thiebaut F., Tsuruo T., Hamada H. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 1989, 37:159-164.
98. Thomas V.H., Bhattachar S., Hitchingham L. The road map to oral bioavailability, an industrial perspective. Expert Opin. Drug Metab. Toxicol. 2006, 2:591-608.
99. Tran T.T., Mittal A., Gales T. Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J. Pharm. Sci. 2004, 93:2108-2123.
100. Troutman M.D., Thakker D.R. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 2003, 20:1200-1209.
101. Troutman M.D., Thakker D.R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 2003, 20:1210-1224.
102. Tsuji A., Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 1996, 13:963-977.
103. Valko K., Du C.M., Bevan C.D. Rapidgradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J. Pharm. Sci. 2000, 89:1085-1096.
104. van Asperen J., van Tellingen O., Beijnen J.H. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 2000, 28:264-267.
105. van de Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44:1313-1333.
106. Wohnsland F., Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artifi cial membranes. J. Med. Chem. 2001, 44:923-930.
107. Xie W., Barwick J.L., Downes M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406:435-439.
108. Zaman G.J., Versantvoort C.H., Smit J.J. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993, 53:1747-1750.
109. Zhang Y., Benet L.Z. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1 MDCK and Caco-2 cell monolayers. Pharm. Res. 1998, 15:1520-1524.
110. Zhu C., Jiang L., Chen T.M., Hwang K.K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 2002, 37:399-407.